Clinical Trials at Nebraska Cancer Specialists
As of August 2026, 40 paid clinical trials are recruiting at Nebraska Cancer Specialists, located at 1299 FARNAM STREET, SUITE 300, OMAHA, NE 68102, phone (800) 557-8950 in Omaha, Nebraska. Active studies at this site cover conditions such as Breast Cancer, Multiple Myeloma and Prostate Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
40 clinical trials at Nebraska Cancer Specialists
·Clear filters·Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
GEMINI-NSCLC: NSCLC Biomarker Study
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Lead-212 PSV359 Therapy for Patients With Solid Tumors
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Common conditions studied in Omaha
- Breast Cancer (15 active studies)
- Multiple Myeloma (14 active studies)
- Prostate Cancer (14 active studies)
- Non-Small Cell Lung Cancer (12 active studies)
- Heart Failure (10 active studies)
- Ovarian Cancer (10 active studies)
Leading research sponsors in Omaha
- University of Nebraska
- National Cancer Institute (NCI)
- AstraZeneca
- Children's Oncology Group
- SWOG Cancer Research Network
Frequently asked questions
How many paid clinical trials are currently recruiting in Omaha?
There are approximately 581 recruiting clinical trials in Omaha, Nebraska listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Omaha pay participants?
Most recruiting trials in Omaha compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Omaha?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Omaha?
The most common conditions under active study in Omaha include Breast Cancer (15), Multiple Myeloma (14), Prostate Cancer (14), Non-Small Cell Lung Cancer (12), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Omaha?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Omaha on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Omaha?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Omaha?
Recruiting research sites in Omaha include University of Nebraska Medical Center, Nebraska Cancer Specialists, Nebraska Medicine-Village Pointe, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Omaha right now?
The largest active categories in Omaha are Cancer & tumors (256), Cardiovascular (40), Diabetes & metabolic (17). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Nebraska Cancer Specialists?
Nebraska Cancer Specialists is located at 1299 FARNAM STREET, SUITE 300, OMAHA, NE 68102. Use the Google Maps link in the intro above to get directions.
How do I contact Nebraska Cancer Specialists?
You can reach Nebraska Cancer Specialists by phone at (800) 557-8950. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.